Botensilimab + Balstilimab
MSS Colorectal Cancer (Chemo-refractory, Unresectable)
Key Facts
About Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileAbout Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileAbout Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileAbout Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileAbout Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profileAbout Agenus
Agenus is focused on developing novel immunotherapies designed to overcome the limitations of first-generation checkpoint inhibitors, particularly in 'cold' or immunologically resistant tumors. The company's most advanced asset, the BOT/BAL combination, has shown promising activity in multiple solid tumors and is now entering registrational studies. With a 30-year legacy in immunotherapy, Agenus leverages a multi-faceted platform to create treatments that aim to deliver deeper and more durable responses for cancer patients.
View full company profile